Michael J Duryee

age ~51

from Omaha, NE

Get Report

Also known as:

Michael M Duryee
Michael J Durvee
Mike Duryee
Michael J Du

Phone and address:: 3213 90Th St, Omaha, NE 68124
402 397-3669

Connected to:

Michael Duryee Phones & Addresses

3213 90Th St, Omaha, NE 68124 • 402 397-3669
6805 B St, Omaha, NE 68106
Grand Island, NE
Crete, NE

Work

Company:

University of nebraska medical center
Jul 2005
Position:

Research coordinator

Education

Degree:

Master of Science, Masters
School / High School:

University of Nebraska Medical Center
1996 to 2000
Specialities:

Immunology

Skills

Clinical Research • Medical Education • Clinical Trials • Animal Models • Lifesciences • Immunohistochemistry • Immunology • Cell Biology • Cancer • Flow Cytometry • Life Sciences • Genetics • Western Blotting • In Vitro • Cancer Research • In Vivo • Molecular Biology • Cell Culture

Industries

Higher Education

Resumes

Research Coordinator

view source

Location:

Omaha, NE

Industry:

Higher Education

Work:

University of Nebraska Medical Center
Research Coordinator

Education:

University of Nebraska Medical Center 1996 - 2000
Master of Science, Masters, Immunology Doane University 1991 - 1995
Bachelors, Bachelor of Science, Biology

Skills:

Clinical Research
Medical Education
Clinical Trials
Animal Models
Lifesciences
Immunohistochemistry
Immunology
Cell Biology
Cancer
Flow Cytometry
Life Sciences
Genetics
Western Blotting
In Vitro
Cancer Research
In Vivo
Molecular Biology
Cell Culture

Us Patents

Biomarker For Coronary Artery Disease
view source
US Patent:

20200249224, Aug 6, 2020
Filed:

Feb 4, 2020
Appl. No.:

16/782015
Inventors:

- Lincoln NE, US
Daniel R. Anderson - Omaha NE, US
Michael J. Duryee - Omaha NE, US
International Classification:

G01N 33/53
G01N 33/68
A61P 9/10
A61K 49/00
G01N 33/564
Abstract:

In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde acetaldehyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction.

Biomarker For Coronary Artery Disease
view source
US Patent:

20180313826, Nov 1, 2018
Filed:

Feb 20, 2018
Appl. No.:

15/900680
Inventors:

- Lincoln NE, US
Daniel R. ANDERSON - Omaha NE, US
Michael J. DURYEE - Omaha NE, US
International Classification:

G01N 33/53
A61K 49/00
G01N 33/564
Abstract:

In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde-acetaldheyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction.

Biomarker For Coronary Artery Disease
view source
US Patent:

20140170068, Jun 19, 2014
Filed:

Mar 12, 2012
Appl. No.:

14/004514
Inventors:

Geoffrey M. Thiele - Omaha NE, US
Daniel R. Anderson - Omaha NE, US
Michael J. Duryee - Omaha NE, US
Assignee:

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA - Lincoln NE
International Classification:

G01N 33/53
A61K 49/00
US Classification:

424 91, 424718, 435 791, 514 56, 514165, 51425212, 514742
Abstract:

In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde-acetaldehyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction.